Genitope Must Continue Trial
A safety monitoring board recommended that Genitope Corp. (GTOP) continue its clinical trials of the cancer vaccine MyVax. The stock price plummeted $2.71 to close at $2.87.
posted by FC Market News at 2:19 PM
0 Comments:
Post a Comment
<< Home